Polymer microneedle for treating acute gout attack and preparation method of polymer microneedle

A gout acute attack, polymer technology, applied in the direction of microneedles, chemical instruments and methods, medical preparations of non-active ingredients, etc., can solve the problems of frequent recurrence and other problems, achieve high drug utilization, good fixed point, easy to use convenient effect

Pending Publication Date: 2021-12-31
深圳前海鹰岗生物科技有限公司
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, some patients only partially respond to this treatment, and often relapse within 1-6 weeks after discontinuation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polymer microneedle for treating acute gout attack and preparation method of polymer microneedle
  • Polymer microneedle for treating acute gout attack and preparation method of polymer microneedle
  • Polymer microneedle for treating acute gout attack and preparation method of polymer microneedle

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0057] First, the production of pharmaceutical preparations

[0058] Monoclonal antibody according to the present embodiment kanamycin pharmaceutical formulation comprising 0.005 to 0.05 parts by weight, 0.05 to 0.15 parts by weight of sodium phosphate, 0.0025-0.025 parts by weight of mannitol and 0.005 to 0.025 parts by weight of sodium chloride. This embodiment previously prepared nanoparticles pharmaceutical preparation, then used in subsequent tests, specifically prepared as follows:

[0059] Weigh 0.12g kanamycin mAb dispersed in phosphate buffer of pH7.1-9.0, adding a small amount of polylactic acid - glycolic acid copolymer solution of polylactic acid - glycolic acid copolymer is used in an amount of about by weight of kanamycin mAb 20% -70% ,, particularly the present embodiment uses 0.06g polylactic acid - glycolic acid copolymer, using a spray dryer made first nanoparticles. Sodium phosphate buffer solution containing 0.36g of sodium phosphate.

[0060] Weigh 0.06g sodiu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
heightaaaaaaaaaa
heightaaaaaaaaaa
Login to view more

Abstract

The invention discloses a polymer microneedle for treating acute gout attack and a preparation method of the polymer microneedle. According to the polymer microneedle disclosed by the invention, a medicinal preparation which is wrapped by a nano material and contains an effective dose of canamazumab is embedded in the needle tip; and the pharmaceutical preparation is prepared from the following components in parts by weight: 0.005-0.05 part of canakumab, 0.05-0.15 part of sodium phosphate, 0.0025-0.025 part of mannitol and 0.005-0.025 part of sodium chloride. According to the microneedle disclosed by the invention, the microneedle patch is directly adhered to a symptom part, so that the use is simple and convenient; by means of nano material wrapping and slow release, the medicine can fully play a role, the better fixed-point and targeted treatment effect is achieved, and the medicine utilization rate is higher; and not only is the problem that the whole body circulation of the canamab is difficult to effectively act on the symptom part for a long time solved, but also various problems caused by excessive use of the canamab in a systemic way are avoided.

Description

Technical field [0001] The present application relates to the treatment of gout technical field, particularly relates to polymer microneedles and a preparation method for the treatment of gout. Background technique [0002] Gout is a common disease worldwide, according to epidemiological statistics, in the 1990s the prevalence of hyperuricemia Europe reported 2% -24%, the United States reported in 1993 hyperuricemia prevalence of 10.1% China 2008 statistics hyperuricemia overall prevalence of 13.2-21.04%. The overall prevalence of gout around the world between 0.13-15.3% of the global annual incidence rate between 0.20% -0.35%. National incidence of gout and hyperuricemia was significantly higher than other countries in Europe and America, and showed a rising trend. Among them, the United States gout prevalence rate is about 3.9%, whereby estimates, there are about 9.2 million US patients; gout patients in Europe and the United States are more than 8 million, the number of Japane...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/00A61K39/395A61K47/02A61K47/22A61K47/26A61K47/34A61K47/38A61P19/02A61P19/06A61P29/00A61M37/00
CPCA61K9/0021A61K47/34A61K47/22A61K47/38A61K47/26A61K47/02A61P19/02A61P19/06A61P29/00C07K16/245A61M37/00A61K2039/505A61M2037/0053
Inventor 霍亮向雄根黎永祥沈芝萍
Owner 深圳前海鹰岗生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap